All members have the option of attending our various HTC-centric events which include:
Date: Tuesday, December 17, 2024
Time: 3:00pm – 4:00pm ET
TOPIC:
HYMPAVZI: An anti-tissue factor pathway inhibitor
OBJECTIVE:
To educate attendees on the novel mechanism of action of HYMPAVZI, the Ph3 clinical trial results and indicated dosage and administration.
INTENDED AUDIENCE:
HCP
SPEAKER:
Dr. Jennifer Schumacher, PhD, Senior Medical Director, Hemophilia
Jennifer Schumacher Sr. Medical Director has over 21 years of Medical Affairs and Biotech Industry experience. Currently, a senior medical director in hemophilia, Jennifer is the US medical lead for marstacimab. During her tenure at Pfizer, she has held several positions beginning in US Medical Affairs in Oncology and transitioning to medical director in Rare Disease where she has lead the global medical team for transthyretin amyloid (ATTR) cardiomyopathy and served as publications lead. Jennifer joined the US hemophilia medical team in 2023.
Jennifer received her PhD in Pharmacology from the University of Minnesota, Minneapolis, USA and a B.S. in Biotechnology and Chemistry from St. Cloud State University, St. Cloud, USA.
Jennifer is based in Minneapolis, Minnesota and enjoys spending time with her husband and two children. She loves reading, cooking and the great outdoors, snowmobiling in the winter and spending time with family and friends at their cabin in the summer.
